{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443822137
| IUPAC_name = 1-[''bis''(4-fluorophenyl)methyl]-4-[(2''E'')-3-phenylprop-2-en-1-yl]piperazine
| image = Flunarizine.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|flunarizine}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| excretion =  

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 52468-60-7
| ATC_prefix = N07
| ATC_suffix = CA03
| PubChem = 941361
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04841
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 819216
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R7PLA2DM0J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07971
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 30008

<!--Chemical data-->
| C=26 | H=26 | F=2 | N=2
| molecular_weight = 404.495
| smiles = Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)C\C=C\c4ccccc4
| InChI = 1/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
| InChIKey = SMANXXCATUTDDT-QPJJXVBHBH
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SMANXXCATUTDDT-QPJJXVBHSA-N
| synonyms = <small>1-[''bis''(4-fluorophenyl)methyl]-4-cinnamyl-piperazine</small>
}}

'''氟桂利嗪'''({{lang|en|Flunarizine}}、2HCL、氟腦嗪、腦靈、西比靈、服腦清)為腦循環系統促進劑，屬於一種[[钙通道阻滞药|钙通道阻滞药]]。<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1987188/ Calium channel blocker]</ref> 氟桂利嗪是一種非選擇性的鈣進入阻滯劑、而其運作包括有"[[組織胺|組織胺]]H1"受體阻斷活性。「它是有效的作為[[偏頭痛|偏頭痛]]、<ref>{{Cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/6343298 |title=Effective in migraine |accessdate=2014-04-27 |archive-date=2014-03-13 |archive-url=https://web.archive.org/web/20140313062113/http://www.ncbi.nlm.nih.gov/pubmed/6343298 |dead-url=no }}</ref> 閉塞性[[外周血管疾病|周邊血管疾病]](Peripheral vascular disease)、中樞和周邊引起的[[暈眩|暈眩]](Vertigo)等病症的預防治療，並作為[[癫痫|癫痫]]治療的佐劑。」它可能有助於減少較嚴重形態的「交替性偏癱」(Alternating hemiplegia)之麻痺性持續發作與嚴重度，以及有效地治療「快速發作的肌張力障礙帕金森病」(rapid onset dystonia-parkinsonism/RDP)。以上的這兩種情況共有{{lang|en|ATP13A}}基因的突變；氟桂利嗪在美國或日本是不允許作為處方藥。<ref>{{Cite web |url=http://www.neurology.org/content/82/6/468.full |title=ATP13A mutation,and response to flunarizine |accessdate=2014-04-27 |archive-date=2015-08-10 |archive-url=https://web.archive.org/web/20150810005127/http://www.neurology.org/content/82/6/468.full |dead-url=no }}</ref> 且氟桂利嗪在成人和兒童身上已經顯著地顯示出減少頭痛發作的頻率和嚴重程度。氟桂利嗪為[[比利時|比利時]][[楊森製藥|楊森製藥]](Janssen Pharmaceutica)於1968年所研創。

==副作用及禁忌==
氟桂利嗪有一定的副作用，包括體重增加、[[錐體外症候群|錐體外系反應]](extrapyramidal effects)、嗜睡和[[情绪抑郁|抑鬱症]]，它[[禁忌_(醫學)|禁忌]](contraindication)於"低血壓"(hypotension)、"心臟衰竭"和"心律失常"(arrhythmia)。抑鬱症、嚴重[[便秘|便秘]]或一些[[錐體外症候群|錐體外症候群]](extrapyramidal disorders)等患者需避免使用氟桂利嗪。

==商標名稱==
* {{lang|en|Sibelium}}(西比靈) 5公絲，[[楊森製藥|楊森製藥]](Janssen Pharmaceutica). Rizelium 5mg and 10mg Capsule by UniMed & UniHealth Mfg. Ltd (孟加拉)。 
* {{lang|en|Fluzine}}(服腦清) <small>(黃色圓形)</small>錠劑5公絲，台灣"生達化學製藥股份有限公司". Fluzine（Flunarizine）Tablets 5mg "Standard"。

==參見==
*[[氰胺鈣|氰胺鈣]](Calcium carbimide)
*[[原纖維蛋白|原纖維蛋白]](Fibrillin)

==註釋==
{{reflist}}

==參考文獻==
{{refbegin}}
* Therapeutic Choices, sixth edition, {{tsl|en|Canadian Pharmacists Association|Canadian Pharmacists Association}}, 2011.
{{refend}}

{{通道阻滞剂}}
{{Antivertigo preparations}}
{{Depressogenics}}

[[Category:钙通道阻滞药|Category:钙通道阻滞药]]
[[Category:抑鬱生成|Category:抑鬱生成]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:楊森製藥|Category:楊森製藥]]
[[Category:比利時發明|Category:比利時發明]]